These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 11109616)
1. [Effects of low-intensity infrared impulse laser therapy on inflammation activity markers in patients with rheumatoid arthritis]. Ilich-Stoianovich O; Nasonov EL; Balabanova RM Ter Arkh; 2000; 72(5):32-4. PubMed ID: 11109616 [TBL] [Abstract][Full Text] [Related]
2. [Neopterin: laboratory marker of cellular immunity activation in rheumatoid arthritis]. Nasonov EL; Samsonov MIu; Chichasova NV; Imametdinova GR; Nikiforova EL; Aleksandrova EN; Ilich-Stoyanovich O; Fux D; Vaxter H Ter Arkh; 1998; 70(5):28-31. PubMed ID: 9644738 [TBL] [Abstract][Full Text] [Related]
3. [Neopterin: new immunological marker of autoimmune rheumatic disease]. Nasonov EL; Samsonov MIu; Tilz G; Fuchs D Klin Med (Mosk); 2000; 78(8):43-6. PubMed ID: 11019525 [TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268 [TBL] [Abstract][Full Text] [Related]
5. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Mahmoud RA; El-Gendi HI; Ahmed HH Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275 [TBL] [Abstract][Full Text] [Related]
15. A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety, and clinical effects. Gao IK; Scholz P; Boehme MW; Norden C; Lemmel EM Rheumatol Int; 2002 Jun; 22(2):45-51. PubMed ID: 12070674 [TBL] [Abstract][Full Text] [Related]
16. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169 [TBL] [Abstract][Full Text] [Related]
17. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452 [TBL] [Abstract][Full Text] [Related]
18. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540 [TBL] [Abstract][Full Text] [Related]
19. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Park MC; Chung SJ; Park YB; Lee SK Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450 [TBL] [Abstract][Full Text] [Related]
20. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]